The Centers for Disease Control and Prevention (CDC) with the help of the American Pharmacists Association (APhA) Foundation has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists, which is intended to improve healthcare quality.
The Centers for Disease Control and Prevention (CDC) with the help of the American Pharmacists Association (APhA) Foundation has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists, which is intended to improve healthcare quality.
The target audience for this resource material is pharmacists, other healthcare providers, payers, and decision-makers of collaborative practice agreements. Under state law, a pharmacist collaborative practice agreement is “a formal agreement in which a licensed provider makes a diagnosis, supervises patient care, and refers patients to a pharmacist under a protocol that allows the pharmacist to perform specific patient care functions,” according to CDC.
“Research shows us that a patient’s control of their blood pressure improves when their care is provided by a team of health professionals,” said David Callahan, MD, with CDC. “This tool kit will play an invaluable role in allowing physicians and pharmacists to work together to give patients optimal are and save lives by controlling blood pressure.”
The content for the tool kit was developed with input from APhA Foundation following a consortium on collaborative practice agreements and pharmacists’ patient care services held in January 2012. Case studies from Osterhous Pharmacy in eastern Iowa, Goodrich Pharmacy in Minnesota, and El Rio Community Health Center in Arizona were good examples of pharmacist patient care services performed under collaborative practice agreements.
The document also outlined action steps for pharmacists to help build and strengthen these collaborative agreements:
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More